Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0002028614 · DMAA · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0002028614 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Drugs Made In America Acquisition Corp. Ordinary Shares (NASDAQ: DMAA) has submitted 68 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Financial Services sector company with CIK 0002028614, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Drugs Made In America Acquisition Corp. Ordinary Shares's most comprehensive regulatory disclosure. The most recent Drugs Made In America Acquisition Corp. Ordinary Shares 10-K was filed on 2026-04-15 for fiscal year ending 2026. Historical DMAA 10-K annual reports are available from 2024 through 2026.
Investors researching Drugs Made In America Acquisition Corp. Ordinary Shares SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
DMAA SEC Filings · 8 questionsDrugs Made In America Acquisition Corp. Ordinary Shares (DMAA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 68 filings and access original documents at no cost. Drugs Made In America Acquisition Corp. Ordinary Shares's CIK is 0002028614.